[Cooperative phase II study of spansule tegafur (SF-SP)].
A phase II study of oral administration of SF-SP alone was conducted in 187 patients with advanced cancers involving 34 institutions in Kinki area. CR was observed in one case of breast cancer, and PR in 29 cases. In 7 responders, response durations of 6 months or more were observed. The drug was effective against colo-rectal, in particular, gastric and breast cancer. No serious toxicity was observed.